Change management activities delivery plan - HMA-EMA joint Big Data Steering Group

Managing product data quality in PMS: processes, known issues, current status and best practices, Online, from 21 July 2026, 14:00 (CEST) to 21 July 2026, 15:30 (CEST)

EMA/PE/0000273488

Human medicines European public assessment report (EPAR): Byannli (previously Paliperidone Janssen-Cilag International), paliperidone, Date of authorisation: 18/06/2020, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Oczyesa, octreotide, Date of authorisation: 30/06/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Vargatef, nintedanib, Date of authorisation: 21/11/2014, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Crysvita, burosumab, Date of authorisation: 19/02/2018, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Jemperli, dostarlimab, Date of authorisation: 21/04/2021, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Zejula, niraparib, Date of authorisation: 16/11/2017, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Slenyto, melatonin, Date of authorisation: 20/09/2018, Revision: 15, Status: Authorised